Xuanzhu Biopharmaceutical Co., Ltd. (SEHK: 2575)
Health Care · Pharmaceuticals · CN
HK$8.38
-4.56% today · -68.2% 1Y
Xuanzhu Biopharmaceutical Co., Ltd. (SEHK: 2575) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $552.76M and employs 342 people.
Over the last twelve months the share price has lost 68.2%, trading between 8.01 and 96.90.
Tweenvest scores Xuanzhu Biopharmaceutical Co., Ltd. across four factors: quality 56/100, value 67/100. Its strongest factor is value.
2575 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $552.76M
- Revenue (TTM)
- $15.21M
- P/E
- —
- EPS
- -0.42
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$96.90
- 52-week low
- HK$8.01
- Avg volume (3M)
- —
- Shares outstanding
- 517.95M
- Employees
- 342
- Next earnings
- —
About Xuanzhu Biopharmaceutical Co., Ltd.
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
- ISIN
- CNE1000074Q1
- Founded
- 2008
- Listed since
- Oct 15, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zhejiang Starry Pharmaceutical Co.,Ltd.SHSE: 603520 | $570.75M | CN¥8.72 | -0.34% |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTDSZSE: 300534 | $567.01M | CN¥12.52 | -0.48% |
| Aclaris Therapeutics, Inc.NasdaqGS: ACRS | $563.77M | $3.83 | +1.06% |
| FDC LimitedBSE: 531599 | $555.31M | Rs330.10 | -1.62% |
| Kingchem (Liaoning) Life Science Co., Ltd.SZSE: 301509 | $545.04M | CN¥30.31 | -3.01% |
| Xiangxue Pharmaceutical Co.,Ltd.SZSE: 300147 | $542.01M | CN¥5.49 | -6.95% |
| Boryung CorporationKOSE: A003850 | $538.78M | ₩8,610.00 | +2.26% |
| Zeria Pharmaceutical Co., Ltd.TSE: 4559 | $535.89M | ¥1,925.00 | +1.42% |
Figures last refreshed Oct 11, 2026.